INTRODUCTION

Primary ovarian insufficiency (POI) or premature ovarian failure (POF) is a heterogeneous gynecological endocrine disease caused by follicular failure or dysfunction. It is characterized by elevated serum gonadotropin level and absence of residual follicles in the gonads, which are associated with oligomenorrhea, amenorrhea, subfertility, and even infertility. The clinical manifestations are hot flashes, sweating, and decreased libido. In POI, the...
process of follicle depletion occurs at a young age (generally taken as 40 years old). The incidence of POI in the general population is estimated to be 1%. In addition, the incidence of POI in women is increasing with age. POI is divided into two types: primary and secondary POI. Primary POI is generally caused by heredity, immune, inflammation, enzyme metabolism disorder, and so on. While unfortunately, the primary cause of POI remains unknown; Secondary POI is generally caused by surgery, radiotherapy, chemotherapy, and other exposure to toxic substances. High-dose radiotherapy and chemotherapy can alleviate cancer in more than 90% of young females, while they have adverse effects on ovarian function and reproductive capacity. The main mechanisms of chemotherapy leading to ovarian dysfunction can be divided into two categories: A. Dysfunction due to direct toxicity to oocytes and ovarian GCs. B. Damage to growing oocytes indirectly leads to over-activation and depletion of primitive oocytes. Ovarian GCs are a layer of parietal cells around the surface of follicles, which support the formation and development of follicles and have the ability to secrete glandular hormones to maintain ovarian function. Aberrant ovarian GC death leads to follicular atresia and decreases the number of follicles. Studies have shown that cyclophosphamide (CTX) does not directly act on oocytes, but induces senescence and apoptosis of GCs in growing follicles, which leads to secondary loss of oocytes. Therefore, inhibiting apoptosis of GCs is the key to prevent chemotherapy-induced POI.

Studies have found that the application of stem cells can rejuvenize follicle and GCs regeneration. These effects may be that mesenchymal stem cells directly migrate to the damaged ovary and differentiate into follicles in the ovarian microenvironment, to promote the recovery of reproductive endocrine and inhibit the apoptosis of GCs, suggesting that transplantation of mesenchymal stem cells can repair the ovarian structure and improve ovarian function. However, stem cell-based therapy still faces some challenges, including transplant rejection, tumor transformation, limited sources, ethical issues, etc., which lead to its limited clinical application. Autologous healthy ovarian tissue transplantation can improve the endocrine level and improve ovarian function, and can effectively restore the reproductive ability of ovarian mice damaged by chemotherapy. Based on this, researchers who were focused on the effective substances in cells found that exosomes derived from cells can be used to treat some diseases. Compared with cells, exosomes have the advantages of low immunogenicity, non-tumorigenicity, high clinical safety, and low ethical risk. Exosomes play a key role in embryonic development, gametogenesis, and fertilization. Many studies have found that exosomes derived from cells can significantly restore the estrous cycle of POI mice, increase the number of basal and antral follicles, inhibit the apoptosis of ovarian GCs. However, its mechanism remains unclear.

Exosomes belong to extracellular vesicles, which are uniform membranous vesicles with a diameter of 30–150 nm. The outer membrane of the vesicles is fused with the cell membrane and released out of the cell. Exosomes carry signal molecules such as mRNA, microRNA (miRNA), circRNA, lncRNA, and protein, and complete the signal transmission between adjacent or distant cells utilizing target cell internalization, ligand-receptor interaction or lipid membrane fusion, and then play important physiological or pathological functions, including coagulation, inflammation, cell expansion, neuronal communication, and tumorigenesis, etc. Furthermore, both normal cells and tumor cells can secrete exosomes. Chemotherapy can alleviate malignant tumors, and also promote their secretion of different exosomes, and their compositions are significantly diverse. For example, annexin 6 and miRNA molecules play an important role in tumor cell metastasis, tumor drug resistance, and other non-tumor cell lesions. It is found that the changes of exosomes and their substances in pathogenic tissues provide a theoretical basis for exploring new diagnostic features, mechanisms, and treatment measures. Therefore, it is a new idea to study the changes of exosomal components in normal or chemotherapy mice ovarian tissue for the treatment of POI.

As an important part of exosomes, miRNA plays an important regulatory role in cell growth, differentiation, communication, and migration, as well as maintaining homeostasis and pathological changes by binding to specific targets. Previous studies have reported that miRNA is differentially expressed in plasma and tissue of POI patients, compared to normal people, which plays an important role in the pathogenesis, diagnosis, and efficacy evaluation of POI. In this study, we cultured ovarian tissues and ovarian GCs of female mice, isolated exosomes from ovarian tissues, identified differentially expressed miRNAs in the ovarian exosomes of CTX-treated mice. Then, we proved the protective effect of normal ovarian exosomes on follicles and revealed that miR-122-5p inhibitor protected ovarian GCs apoptosis induced by CTX through target gene BCL9, which provided the cytological basis for further in vivo experiments.

2 | Materials and methods

2.1 | Animals

Female ICR mice (Charles River, Beijing, China) have high survival rate and strong reproductive ability and were
used as experimental animals, which were raised at room temperature, humidity 45%–55% and illumination time 12 h. The study was conducted according to the guidelines of the Declaration of Helsinki. All experimental research steps involving these animals were subject to approval by the Medical Ethics Committee of the Shandong Provincial Hospital Affiliated to Shandong First Medical University (approval no.2019132, 14 November 2020).

2.2 | Establishment of mouse POI model

The female ICR mice aged from 6 to 8 weeks, were injected intraperitoneally (I.P.) with CTX (20 mg per kg of body weight daily) and busulfan (8.75 mg per kg of body weight daily) (Otsuka America) for 2 weeks. In the control group, ICR female mice were injected with phosphate-buffered saline (PBS) at the same dose intraperitoneally. Two weeks later, the animals were sacrificed, tissues were collected.

2.3 | Ovarian histological characteristics

Immediately after mice were sacrificed, the bilateral ovaries were dissected and fixed in 75% alcohol for 5 min. In the ultra-clean table, cut the abdominal wall, take out the bilateral ovaries, quickly put them into a 35-mm Petri dish containing PBS (preheated at 37°C), fix them with 4% paraformaldehyde (Solarbio). After 24 h of fixation, increasing concentrations of ethanol dehydrated the ovarian tissue, xylene (Solarbio, Beijing, China) clarified the ovarian tissue, and the tissues were paraffin-embedded. The paraffin was sectioned (4 µm thick) for hematoxylin and eosin staining to observe the morphological structure of the mouse ovaries under an optical microscope.

2.4 | Isolation, culture, and different treatment of ovarian GCs

Three-week-old ICR female mice were intraperitoneally injected with 10 IU of pregnant mare serum gonadotropin (Jinke). After 24 h, these mice were euthanized, and their ovaries were isolated mechanically. Ovarian GCs were obtained by puncturing follicles under a stereomicroscope. Then complete medium (DME/F-12 1:1 [1×], 10% FBS, 3.7 mg/ml NaHCO₃, and 1% Penicillin–Streptomycin) was added to ovarian GCs and incubated in a 37°C in a humidified atmosphere with 5% CO₂. GCs were inoculated into six-well plates with 2 × 10⁶ cells per well. GCs with an adhesion rate of 50%–60% were selected for follow-up experiments and divided into two groups: one group was added with 2 µM CTX; the other group added the same amount of PBS as the control group; cultured for 24 h to induce apoptosis of GCs.

2.5 | Isolation and identification of ovarian tissue-derived exosomes

ICR female mice aged 6 weeks were selected. After 2 weeks of treatment with the above chemotherapy regimen, the mice were sacrificed, ovarian tissues were collected, and cultured in DMEM containing 100 U/ml Penicillin and 100 µg/ml Streptomycin in a humidified incubator of 5% CO₂ at 37°C. After 24 h, exosomes were extracted by gradient ultracentrifugation. The collected supernatant of ovarian tissue was centrifuged at increasing speeds of 300×g for 10 min, 2000× g for 10 min, 3000× g for 15 min to remove cell debris with 0.22 µm filter, and 10,000× g at 4°C for 30 min to remove sediment and debris. Then, the supernatant was centrifuged twice at 120,000×g for 80 min in clear ultracentrifuge tubes, resuspend the precipitate with 200 µl of particle-free PBS. To confirm the successful isolation of the separated and purified exosomes, western blot was used to identify the characteristic marker proteins of the exosome, including CD63 and CD81 (Affinity). Then observing the difference in quantity, shape, and size of exosomes from two groups under transmission electron microscopy (TEM), and taking pictures.

2.6 | Effect of exosomes on apoptosis of ovarian GCs

Exosomes extracted from ovarian tissues were co-cultured with ovarian GCs. The GCs in the six-well plate were divided into two groups: one group was added PBS as the control group; the other group was added with 2 µM CTX. Cultured for 24 h to induce apoptosis of GCs. CTX group was then divided into two groups, were added exosomes derived from ovarian tissue of POI mice and normal mice, respectively. Cells were gathered after 48 h.

2.7 | Flow cytometry assay

According to the manufacturer’s procedure, CTX-induced granulosa cell (GC) apoptosis was determined by FACS using FITC Annexin V/PI Apoptosis Detection Kit. In short, cells were seeded in six-well plates at a density of 5 × 10⁵. After 2 days, the cells were washed three times with cold PBS and stained with FITC Annexin V and propidium iodide (PI) for 15 min at room temperature using the Annexin V-FITC Apoptosis Detection Kit. Then we analyzed the stained cells by fluorescence-activated cell sorting (FACS).
2.8 | Exosome-derived miRNA high-throughput sequencing (miRNA-seq)

Exosomes were extracted from ovarian tissues of normal group and POI group, centrifuged at 2000 g for 5 min, and then resuspend the precipitate with 200 μl of particle-free PBS. RNA was extracted separately and sent to the company (RiboBio) for miRNA high-throughput sequencing.

2.9 | Quantitative real-time polymerase chain reaction

Total RNA was extracted using Trizol reagent (Invitrogen), cDNA was synthesized by reverse transcription (Thermo Fisher Scientific). SYRB Green PCR Kit (CWBiO) were used for quantitative real-time polymerase chain reaction (qRT-PCR) analysis. All qRT-PCR reactions were tested in triplicates with the following thermocycling conditions: 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 30 s and 72°C for 32 s on a CFX96™ Real Time PCR Detection system (Bio-Rad). The relative levels of gene expression were quantified using 2−ΔΔCt method. GAPDH was used as an internal control for all samples. The BCL9 primer sequence as follows: 5′-CGGGGACTTGGATGTGAG-3′ and 5′-TTTCAAGAGGTCCACTCCGC-3′.

2.10 | Western blot

Ovarian tissue-derived exosomes were lysed in RIPA buffer with protease inhibitor cocktail (Sigma). The lysates were resolved on SDS–PAGE and transferred onto 0.22 μm PVDF membrane (Millipore), and then blocked with 5% skim milk for 2 h at room and then incubated with primary antibodies at 4°C overnight. Primary antibodies at the following dilutions: BCL9 (1:1000, ab37305; Abcam), β-actin (1:1000, #4970; CST). Subsequently, incubated with horseradish peroxidase-conjugated secondary antibody (1:5000 dilution) for 2 h at room temperature. A complex of primary and secondary antibodies labeled was detected by an enhanced chemiluminescence (Millipore) system followed by exposure to Amersham Imager 600.

2.11 | Immunohistochemistry

Ovarian tissue of mice preserved in 4% paraformaldehyde was dehydrated and embedded in paraffin. The ovarian tissue was cut into 4 μm thick slices, dewaxed in gradient ethanol and xylene, and then immersed in the PBS. After rehydration, the membrane-breaking solution broke the cell membrane, then degreased with 3% hydrogen peroxide methanol. Then the membrane was incubated with primary antibody for 12 h at 4°C in a humid environment. Subsequently, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody for 50 min at room temperature. Ovarian slices were stained with a DAB kit (Solarbio), counterstained with hematoxylin, and sealed with neutral resin after dehydration. The difference between the control group and the administration group was observed under an optical microscope. At last, immunoblot densitometry was performed using Image J software.

2.12 | Effect of miR-122-5p on apoptosis of GCs

To further clarify whether miR-122-5p can protect ovarian GCs from CTX injury, 2 μM CTX was added to GCs to induce apoptosis of cells; 24 h after culture, the group was set up into four groups, followed by adding miR-122-5p mimic NC, miR-122-5p mimic, miR-122-5p inhibitor NC, and miR-122-5p inhibitor (RiboBio). Twenty-four hours later, the cells were collected, and the effects of miR-122-5p mimic and inhibitor on apoptosis of GCs was detected by PI/Annexin-V flow cytometry. The transfection efficiency was assessed by qRT-PCR and western blot at 24 h after transfection.

2.13 | Statistical analysis

GraphPad Prism 8 (GraphPad Software, Inc.), Image J (Image J software, Inc.), and SPSS 22.0 (SPSS software, Inc.) were used for statistical analysis. Comparisons between groups were analyzed by the t-test and X2 test. Data are presented as the mean ± SD of three independent experiments. Results were considered statistically significant for p < 0.05.

3 | Results

3.1 | Effect of chemotherapy drugs on mouse ovary and GCs

After 2 weeks of treatment with CTX and busulfan, the POI model of ICR female mice was successfully established. The ovarian morphological characteristics between the control group and the POI group were compared. In the control group, the mouse ovaries had large and...
abundant follicles, abundant follicular fluid, and multiple corpus luteum. While in the POI group the ovaries had few and mostly primitive or initial follicles, and the atresia follicles and interstitium were increased due to GCs injury (Figure 1A). In the cell cultural model, microscopic observation showed that 48 h after inoculation with CTX at the concentration of 2 μM, the treated GCs adhered and grew in the visual field, showing polygonal, fibrous structures, and pseudopodium. Compared with the control group, CTX treatment also reduced the number of the cells (Figure 1B).

3.2 | Extraction and characterization of ovarian exosomes

Exosomes were extracted from ovarian tissue using gradient ultracentrifugation. Ovarian tissue-derived exosomes were characterized by morphological observation and marker protein detection. By TEM, membranous vesicles were uniform size, round or oval shape, with clear margins, and double lipid membranes surrounding them (Figure 2A). The morphological analysis showed that the size distribution of exosome intensity was 50–150 nm.

**FIGURE 1** Typical characteristics of the ovary and granulosa cells (GCs) of normal and mice treated with chemotherapy drugs. (A) Histological analysis of ovarian sections of 6 weeks old mice after 2 weeks of treatment with (right) or without (left) cyclophosphamide (CTX) and busulfan, a representative hematoxylin and eosin staining of 15 mouse ovaries. Scale bar: 100 μm; (B) A representative GCs morphology of normal (left) or with CTX treatment (right), the cells were polygonal and fiber-like; compared with the control group, the number of ovarian GCs in the CTX group was significantly reduced. Scale bar: 50 μm
There was no significant difference in the shape and size of ovarian exosomes between the control and the POI groups. FACS analysis showed positivity of the typical exosomal surface marker proteins CD63 and CD81 (Figure 2C).

### 3.3 Effects of ovarian exosomes on CTX-damaged ovarian GCs

To further assess the therapeutic role of exosomes derived from normal ovarian tissue in CTX-damaged ovarian GCs, CTX-injured cells were co-cultured with ovarian exosomes extracted from the control group and the POI group, respectively. Flow cytometry analysis showed that CTX promoted apoptosis of GCs ($p < 0.001$, Figure 3A). The proportion of apoptotic cells in the exosome-POI group was higher than that in the exosome-NC group, indicated that ovarian exosomes extracted from POI mice promoted apoptosis of GCs, while the control ovarian tissue-derived exosomes ameliorated the status of GCs damaged by CTX ($p < 0.01$, Figure 3B). The data indicate that that healthy ovarian tissue-derived exosomes could reverse the course of POI in the CTX mouse model.
3.4 Identification of miRNAs in exosomes of normal mice and POI models

In the research, it was found by high-throughput sequencing that the expression profiles of miRNAs in ovarian exosomes of the control group and the POI group were markedly different. There were 30 miRNAs upregulated or downregulated by more than two times, among which miR-122-5p related to apoptosis is upregulated by more than 32-times in the ovarian exosomes of the chemotherapy group (Figure 4A). To further determine the role of miRNAs in CTX-induced POI, we first assessed the transcription level of miR-122-5p and miR-141-3p by using qRT-PCR, the result showed that their expression levels in ovarian exosomes of the POI group were significantly higher than those in the control group (Figure 4B). We further explored their downstream targets in signal pathways were also altered, the results of qRT-PCR and western blot assay showed that BCL9, the target molecule of miR-122-5p, was indeed significantly downregulated in the ovary of the POI group compared with the control group, while TAP-63 is the opposite. (Figure 4C–E). Immunohistochemistry analysis further confirmed that the expression of BCL9 was downregulated in the ovarian tissues of the POI mice (Figure 4F,G).

3.5 miR-122-5p regulates apoptosis of ovarian GCs

To further study the effect of exosomal miR-122-5p on ovarian GCs, miR-122-5p mimics, and inhibitors were selected for further analysis. miR-122-5p mimic NC, miR-122-5p mimic, miR-122-5p inhibitor NC, and miR-122-5p inhibitor were co-cultured with CTX-damaged ovarian GCs. Flow cytometry analysis showed that CTX promoted apoptosis of GCs (Figure 5A). The proportion of apoptotic cells in the miR-122-5p mimic group was higher than that in the miR-122-5p mimic NC group, indicated that miR-122-5p promoted apoptosis of GCs (Figure 5B). Compared with the control group, the proportion of apoptotic cells in the miR-122-5p inhibitor NC group increased, while the miR-122-5p inhibitor reduced the apoptosis of GCs (Figure 5C). The results indicate that miR-122-5p inhibitor inhibits apoptosis of ovarian GCs injured by CTX.

FIGURE 3 The effect of ovarian exosomes extracted from normal and POI mice on apoptosis of cultured GCs. (A, B) Exosomes protect against CTX-induced injury of GCs and promote resistance to cell apoptosis in vitro based on FACS. Groups were cultured for 48 h, through PI/Annexin-V double staining and FACS analysis. CTX+ Exos-NC, CTX+ exosomes from normal mice ovarian tissue. CTX+ Exos-POI, CTX+ exosomes from POI mice ovarian tissue.
To further evaluate the mechanism by which the ovarian exosomal miR-122-5p promotes apoptosis of ovarian GCs, the transcription levels of BCL9 and miR-122-5p in ovarian GCs of the CTX group was significantly upregulated compared with that in the control group, while the expression of BCL9 was the opposite (Figure 6A). Western blot analysis showed that CTX significantly inhibited the expression of BCL9 in ovarian GCs (Figure 6B,C). In order to further check if miR-122-5p inhibitor could reverse the detrimental effect caused by CTX treatment, CTX-damaged GCs were incubated for 2 days in cell culture medium containing the miR-122-5p inhibitor. The results showed that the miR-122-5p inhibitor could significantly reverse the apoptosis of GCs caused by CTX, as evidenced by the upregulation of BCL9 expression (Figure 6D). These findings suggest that miR-122-5p plays a crucial role in the regulation of ovarian GC apoptosis via the BCL9 pathway.
inhibitor and analyzed by qRT-PCR (Figure 6D) and western blot assay indicated that BCL-9 was upregulated (Figure 6E,F). The data confirmed that (1) miR-122-5p is upregulated, (2) the role of the signal pathway of miR-122-5p/BCL9 in the course of POI and its therapeutic application in chemotherapy-induced POI, and (3) mir-122-5p inhibitor can protect GCs from apoptosis by upregulating BCL9 expression.

FIGURE 5 The effect of miR-122-5p on apoptosis of ovarian GCs. Flow cytometry analysis was used to analyze GCs apoptosis after increasing and reducing the expression of miR-122-5p in the group. (A) CTX-induced apoptosis of ovarian GCs. (B) miR-122-5p mimic promoted apoptosis of GCs. (C) miR-122-5p inhibitor weakened the apoptosis of GCs.

4 | DISCUSSION

Currently, in a survey of cancer patients in 25 countries, the 5-year net survival rate of women diagnosed with cancer between 2010 and 2014 is 85% or higher, and the survival rate of young cancer patients is significantly higher than that of elderly patients. In China, the survival rate of breast cancer patients under 35 years old is 90.91%, and
that of patients aged 35–45 years old is 57.84%. For POI induced by chemotherapy, the damage to the ovary is different according to the scope of chemotherapy and radiotherapy, the age of the patient, the type of medication, and the dosage. Among the chemotherapy drugs, the alkylated drugs do the greatest harm to the ovary. Therefore, in this experiment, we selected common clinical animal models of POI induced by CTX combined with busulfan as well as a cell model of ovarian GCs injury induced by CTX in vitro. Studies have shown that intraperitoneal injection of CTX combined with busulfan can cause endocrine dysfunction and ovarian tissue damage in mice, leading to ovarian failure.

Chemotherapy may cause irreversible ovarian damage, so the fertility preservation of women of childbearing age and adolescent women during the anticancer period is extremely significant. However, fertility preservation methods recommended by the American Reproductive Medicine Association are to preserve the couples' embryos and the female oocytes. Although hormone replacement therapy can be used for a long time to relieve symptoms, it cannot prevent its occurrence and progress. Besides,
ovarian tissue transplantation and stem cell transplantation cannot cure POI, due to their poor prognosis and uncontrollable long-term results. Therefore, it is urgent to find a new clinical treatment strategy for POI patients. To date, increasing evidence shows that the therapeutic activities of stem cells and ovarian cells through the paracrine process, which leads to a novel concept of “cell-free” therapy.

Based on reports, exosomes are a new way of interaction between cells. Exosomes are nano-scale biological lipid double-membrane vesicle carriers with stable biological characteristics, and their molecular markers are integrins, CD24, CD63, CD81, CD91, HSPA8, and HSC70. The vesicles contain MHC I and MHC II, lipids, adhesion proteins, and nucleic acid components, which release vesicles (exosomes) and combine with cell membranes in a calcium-dependent manner. In recent years, studies have confirmed that exosomes derived from cells are effective in treating diseases such as liver failure, heart failure, and ovarian cancer by transferring proteins and RNA. In addition, exosomes also play a key role in various aspects of dysplasia, including embryonic development, gametogenesis, and fertilization. Exosomes derived from human umbilical cord mesenchymal stem cells and bone marrow mesenchymal stem cells can significantly upregulate the level of BCL-2 and downregulate the level of Caspase-3 in the cisplatin-induced POI model, suggesting that exosomes can protect ovarian GCs from apoptosis induced by chemotherapy drugs. In our study, we investigated the role of ovarian tissue-derived exosomes in CTX-induced apoptosis of GCs in mice. The results showed that the exosome derived from ovarian tissue in normal mice significantly weakened the apoptosis of ovarian GCs, while the exosome derived from ovarian tissue in POI mice deteriorated the apoptosis of ovarian GCs. The results indicate that the exosomes derived from normal ovarian tissues have a protective effect on GCs injury.

The abnormal expression of miRNAs is closely related to many diseases. For example, the exosomal miR-205 from cancer cells can regulate angiogenesis and tumor metastasis; miR-106a is closely related to ovarian development; Transfection of anti-miR-106a or pre-miR-591 enhances apoptosis of ovarian cancer cell SKpac, and inhibits cell migration and proliferation. Researchers have found that the exosome miR-10a derived from amniotic fluid stem cells, the exosome miR-644-5p derived from bone marrow mesenchymal stem cells and miR-144-5p can inhibit the apoptosis of damaged GCs, prevent follicular atresia after chemotherapy, and improve ovarian failure caused by chemotherapy. In addition, human umbilical cord mesenchymal stem cells miR-17-5p and human amniotic mesenchymal stem cells miR-320a can restore ovarian vitality, increase the number of follicles, restore hormone levels, and improve POI. Therefore, the identification of exosome-mediated cell-cell interaction may provide a new strategy for the clinical treatment of POI. Therefore, we determined to identify the difference of miRNAs in exosomes derived from ovarian tissues of POI mice and normal mice.

The high-throughput sequencing of ovarian exosomes in the POI group and control group showed that there were significant differences in the expression of various miRNAs, miR-141-3p, and miR-122-5p in ovarian exosomes in chemotherapy group were significantly upregulated, among which the apoptosis-related miR-122-5p was upregulated more than 32 times in ovarian exosome in the chemotherapy group. Previous studies have shown that the enhanced expression of miR-141-3p suppressed the proliferation and migration of ectopic ESCs and promoted their apoptosis via targeting KLF-12. In addition, the study showed that miR-141-3p was dramatically decreased in the ovaries of rat PCOS models. Researchers transfected miR-141-3p mimics, and the results showed that miR-141-3p inhibited the apoptosis of rat ovarian GCs. However, our research contradicts it, so we choose to study miR-122-5p. As a specific miRNA molecule of liver cells, it accounts for nearly 70% of the total miRNA. It is known that miR-122-5p can inhibit tumors, and its expression in hepatocellular carcinoma, breast carcinoma, endometrial carcinoma, and ovarian cancer are significantly reduced, so overexpression of miR-122-5p can reduce the tumorigenicity of cancer cells. In addition, miR-122-5p plays an important role in maintaining liver development and regulating cholesterol biosynthesis, and it also plays a vital role in stabilizing HBV and HCV mRNA and virus transmission.

Besides, we selected the target factors BCL9 and TAP-63, and the results of qPCR showed that miR-122-5p could downregulate the target factor BCL9, while TAP-63 was the opposite, so we chose to study BCL9. BCL9 is highly expressed in human tumor tissues, and β-catenin/BCL9 is an important target for cancer treatment. However, the relationship between miR-122-5p target gene BCL9 and its protein expression and POI has not been reported in the literature. Our research shows that miR-122-5p in ovarian tissue-derived exosomes promotes GC apoptosis by regulating the expression of BCL9, and it is speculated that POI can be improved by regulating ovarian GCs apoptosis. In the future study, the effects of miR-122-5p on ovarian function will be detected in vivo.

In this study, our results suggest that ovarian tissue exosomal miRNAs is involved in the regulation of POI after chemotherapy. Clarifying the function and mechanism of miR-122-5p in chemotherapy-induced ovarian damage
will help to reveal the molecular regulation mechanism of POI, and provide a new target for protecting ovarian function. Exosomes play a key role in restoring ovarian function induced by CTX, which mainly regulates the expression of BCL9 by delivering miR-122-5p to ovarian GCs, thus intervening with apoptosis. Our current study clarified the potential molecular mechanism of ovarian function recovery and provided new strategies and directions for POI treatment.

ACKNOWLEDGMENTS
The authors thank the participants and staff for their help and support in the study.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
Xiujuan Zhang, Ruihong Zhang, and Yu-Lan Mu conceived and designed the experiments; Xiujuan Zhang, Ruihong Zhang, Jing Hao, performed the experiments; Xiaoyan Huang, Ming Liu, and Mengxiao Lv analyzed the data; Xiujuan Zhang, Ruihong Zhang wrote the paper. Jing Hao and Yu-Lan Mu reviewed and edited the paper.

ETHICS STATEMENT
The protocol was reviewed and approved by the Medical Ethics Committee of the Shandong Provincial Hospital Affiliated to Shandong First Medical University.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Xiujuan Zhang https://orcid.org/0000-0003-3955-0301
Ming Liu https://orcid.org/0000-0003-1982-0095

REFERENCES
1. Huang B, Lu J, Ding C, Zou Q, Wang W, Li H. Exosomes derived from human adipose mesenchymal stem cells improve ovary function of premature ovarian insufficiency by targeting SMAD. Stem Cell Res Ther. 2018;9(1):216. doi:10.1186/s13287-018-0953-7
2. Ding C, Li H, Wang Y, et al. Different therapeutic effects of cells derived from human amniotic membrane on premature ovarian aging depend on distinct cellular biological characteristics. Stem Cell Res Ther. 2017;8(1):173. doi:10.1186/s13287-017-0613-3
3. Rudnicka E, Kruszewska J, Klicka K, et al. Premature ovarian insufficiency - aetiology, epidemiology, and diagnostic evaluation. Prz Menopauzalny. 2018;17(3):105-108. doi:10.5114/pm.2018.78550
4. Nuovo S, Passeri M, Di Benedetto E, et al. Characterization of endocrine features and genotype-phenotypes correlations in blepharophimosis-ptosis-epicanthus inversus syndrome type 1. J Endocrinol Invest. 2016;39(2):227-233. doi:10.1007/s40618-015-0334-3
5. Chang SH, Kim CS, Lee KS, et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas. 2007;58(1):19-30. doi:10.1016/j.maturitas.2007.04.001
6. Wang H, Chen H, Qin Y, et al. Risks associated with premature ovarian failure in Han Chinese women. Reprod Biomed Online. 2015;30(4):401-407. doi:10.1016/j.rbmo.2014.12.013
7. Salama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological malignancies A multidisciplinary oncofertility approach. Ann Oncol. 2019;30(11):1760-1775. doi:10.1093/annonc/mdz284/555073
8. Kerr JB, Myers M, Anderson RA. The dynamics of the primordial follicle reserve. Reproduction. 2013;146(6):R205-R215. doi:10.1530/rep-13-0181
9. Zhang Y, Yan Z, Qin Q, et al. Transcriptome landscape of human folliculogenesis reveals oocyte and granulosa cell interactions. Mol Cell. 2018;72(6):1021-1034 e4. doi:10.1016/j.molcel.2018.10.029
10. Xiong Y, Liu T, Wang S, Chi H, Chen C, Zheng J. Cyclophosphamide promotes the proliferation inhibition of mouse ovarian granulosa cells and premature ovarian failure by activating the IncRNA-Meg3-p53-p66Shc pathway. Gene. 2017;596:1-8. doi:10.1016/j.gene.2016.10.011
11. Dang J, Jin Z, Liu X, Hu D, Wang Z. Human cord blood mononuclear cell transplantation for the treatment of premature ovarian failure in nude mice. Int J Clin Exp Med. 2015;8(3):4122-4127.
12. Sheikhansari G, Aghebati-Maleki L, Nouri M, Jadidi-Niaragh F, Yousefi M. Current approaches for the treatment of premature ovarian failure with stem cell therapy. Biomed Pharmacother. 2018;102:254-262. doi:10.1016/j.biopharma.2018.03.056
13. Batchvarov IS, Taylor RW, BustamanteMarín X, et al. A grafted ovarian fragment rescues host fertility after chemotherapy. Mol Hum Reprod. 2016;22(12):842-851. doi:10.1093/molehr/gaw064
14. Yang W, Zhang J, Xu B, et al. HucMSC-derived exosomes mitigate the age-related retardation of fertility in female mice. Mol Ther. 2020;28(4):1200-1213. doi:10.1016/j.ymthe.2020.02.003
15. Shah R, Patel T, Freedman JE. Circulating extracellular vesicles in human disease. N Engl J Med. 2018;379(10):958-966. doi:10.1056/NEJMr1704286
16. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228. doi:10.1038/nrm.2017.125
17. Bandari SK, Purushothaman A, Ramani VC, et al. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 2018;65:104-118. doi:10.1016/j.matbio.2017.09.001
18. Keklikoglou I, Cianciaruso C, Güç E, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019;21(2):190-202. doi:10.1038/s41556-018-0256-3
19. Alharbi M, Zuñiga F, Elfeky O, et al. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocr Relat Cancer. 2018;25(12):R663-R685. doi:10.1530/ERC-18-0019
20. Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of exosome composition. *Cell*. 2019;177(2):428-445 e18. doi:10.1016/j.cell.2019.02.029

21. Guo Y, Sun J, Lai D. Role of microRNAs in premature ovarian insufficiency. *Reprod Biol Endocrinol*. 2017;15(1):38. doi:10.1186/s12958-017-0256-3

22. Yang M, Lin L, Sha C, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN. *Lab Invest*. 2020;100(3):342-352. doi:10.1038/s41374-019-0321-y

23. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet (London, England)*. 2018;391(10125):1023-1075. doi:10.1016/s0140-6736(17)33326-3

24. Chen JG, Chen HZ, Zhu J, et al. Cancer survival in patients from a hospital-based cancer registry, China. *J Cancer*. 2018;9(5):851-860. doi:10.7150/jca.23039

25. Bildik G, Akin N, Senbabaoglu F, et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. *Hum Reprod*. 2015;30(12):2912-2925. doi:10.1093/humrep/dev257

26. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. *Fertil Steril*. 2018;110(3):380-386. doi:10.1016/j.fertnstert.2018.05.034

27. Kano M, Sosulski AE, Zhang L, et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. *Proc Natl Acad Sci USA*. 2017;114(9):E1688-E1697. doi:10.1073/pnas.1620729114

28. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. *Trends Mol Med*. 2010;16(5):203-209. doi:10.1016/j.molmed.2010.02.005

29. Sun L, Li D, Song K, et al. Exosomes derived from human umbilical cord mesenchymal stem cells protect against cisplatin-induced ovarian granulosa cell stress and apoptosis in vitro. *Sci Rep*. 2017;7(1):2552. doi:10.1038/s41598-017-02786-x

30. Sun B, Ma Y, Wang F, Hu L, Sun Y. miR-644-5p carried by bone mesenchymal stem cell-derived exosomes targets regulation of p53 to inhibit ovarian granulosa cell apoptosis. *Stem Cell Res Ther*. 2019;10(1):360. doi:10.1186/s13287-019-1442-3

31. He L, Zhu W, Chen Q, et al. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. *Theranostics*. 2019;9(26):8206-8220. doi:10.7150/thno.37455

32. Huh JH, Kim TH, Kim K, et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. *Br J Cancer*. 2013;109(2):452-461. doi:10.1038/bjc.2013.305

33. Xiao GY, Cheng CC, Chiang YS, Cheng WT, Liu IH, Wu SC. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. *Sci Rep*. 2016;6:23120. doi:10.1038/srep23120

34. Ding C, Zhu L, Shen H, et al. Exosomal miRNA-17-5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7. *Stem Cells*. 2020;38(9):1137-1148. doi:10.1002/stem.3204

35. Ding C, Qian C, Hou S, et al. Exosomal miRNA-320a is released from hAMSCs and regulates SIRT4 to prevent reactive oxygen species generation in POI. *Mol Ther Nucleic Acids*. 2020;21:37-50. doi:10.1016/j.omtn.2020.05.013

36. Zhong Y, Yan J, Pan X. miR-141-3p affects apoptosis and migration of endometrial stromal cells by targeting KLF-12. *Eur J Physiol*. 2019;471(8):1055-1063. doi:10.1007/s00424-019-02282-2

37. Li D, Xu D, Xu Y, et al. MicroRNA-141-3p targets DAPK1 and inhibits apoptosis in rat ovarian granulosa cells. *Cell Biochem Funct*. 2017;35(4):197-201. doi:10.1002/cbf.3248

38. Yin S, Fan Y, Zhang H, et al. Differential TGFbeta pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. *Nat Commun*. 2016;7:11012. doi:10.1038/ncomms11012

39. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. *RNA Biol*. 2004;1(2):106-113. doi:10.4161/rna.1.2.1066

How to cite this article: Zhang X, Zhang R, Hao J, et al. miRNA-122-5p in POI ovarian-derived exosomes promotes granulosa cell apoptosis by regulating BCL9. *Cancer Med*. 2022;11:2414–2426. doi:10.1002/cam4.4615